<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250111064343N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-03-10</date_registration>
      <primary_sponsor>Bandare-abbas University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of aromatherapy on the anxiety of patients who are candidates for angiography</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of lavender and chamomile scent on anxiety in patients who are candidates for angiography</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-04-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/82209</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: The sampling method of this study is non-probability. In this way, patients who meet the inclusion criteria and complete the consent form to participate in the study will be considered as the study sample of this study until the desired number of samples is completed. Then, using the random block method (selection of 10 blocks of 15), we allocate the sample individuals to one of the three study groups (lavender, chamomile, or placebo) according to the random sequence table extracted in the Randomization Maine software at the Internet address https://www.randomizer.org/, Blinding description: Single-blinding in this study means that the participants simply do not know which scent they will be exposed to. (While the patients are able to identify the scents, they do not know which particular scent is the active intervention being tested.).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Anxiety of angiography patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: First intervention group (aromatherapy with lavender essential oil): After assigning individuals to the intervention and placebo groups, the level of latent and overt anxiety will be measured using the Spielberger questionnaire. The second step: About an hour before angiography, for the lavender aromatherapy group, 2 drops of 10% lavender essential oil (provided by Barij Essential Oil Company) will be poured onto a 10 x 10 cm piece of cloth using a dropper and pinned to the patients' shirts 20 cm from their noses. Then, immediately 20 minutes after the intervention, the patients' level of anxiety will be measured again using the Spielberger questionnaire, and the data will be collected and analyzed. Finally, the results of the interventions between the groups, as well as before and after the intervention, will be analyzed and compared. Intervention 2: Intervention group: Second intervention group (aromatherapy with chamomile essential oil): After assigning individuals to the intervention and placebo groups, the level of latent and overt anxiety will be measured using the Spielberger questionnaire. The second step is that about an hour before angiography, for the aromatherapy with chamomile essential oil group, 2 drops of 10% chamomile essential oil will be poured onto a 10 x 10 cm piece of cloth using a dropper and pinned to the patients' shirts at a distance of 20 cm from their noses. Then, immediately 20 minutes after the intervention, the patients' level of anxiety will be measured again using the Spielberger questionnaire, and data will be collected and analyzed. Finally, the results of the interventions between the groups, as well as before and after the intervention, will be analyzed and compared. Intervention 3: Control group: (Aromatherapy with distilled water): After assigning individuals to the intervention and placebo groups, the level of latent and overt anxiety will be measured using the Spielberger questionnaire. The second step is that about an hour before angiography, for the placebo group, 2 drops of distilled water will be poured onto a 10 x 10 cm piece of cloth using a dropper and pinned to their shirt 20 cm from the patients' noses. Then, immediately 20 minutes after the intervention, the patients' level of anxiety will be measured again using the Spielberger questionnaire, and the data will be collected and analyzed. Finally, the results of the interventions between the groups, as well as before and after the intervention, will be analyzed and compared.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only information about the outcome

When:
Since 1403

To whom:
The data will be available to all healthcare researchers.

Conditions:
It will be used for research and educational purposes.

Where to obtain:
Ms. Niloofar Rabbani, a senior student of surgical nursing at Hormozgan University of Medical Sciences, can be reached via email at niloo.rbn1998@gmail.com and phone number 09301850138.

How to obtain:
Access to the data file will be possible by sending a request to the author's email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Niloofar Rabbani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Beginning of Imam Hossein Boulevard, Hormozgan University of Medical Sciences, Faculty of Nursing and Midwifery</address>
        <city>Bandar abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7919693116</zip>
        <telephone>+98 930 185 0138</telephone>
        <email>niloo.rbn1998@gmail.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Aref Faghih</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Beginning of Imam Hossein Boulevard, Hormozgan University of Medical Sciences, Faculty of Nursing and Midwifery</address>
        <city>Bandar abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7919693116</zip>
        <telephone>+98 76 3128 5022</telephone>
        <email>aref_faghih@yahoo.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having informed consent
Age range from 18 to 65 years
Having complete alertness
Absence of any allergy to medicinal plants
Candidate patients for coronary angiography for the first time
Failure to perform other invasive procedures before angiography (such as echocardiography through the esophagus)
Absence of valvular heart disease, any olfactory and respiratory problems, drug addiction, liver and kidney problems.
Not taking sedative drugs 4 hours before the intervention</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unwillingness to participate in the study
History of any confirmed mental illness, such as depression and anxiety
The occurrence of any cardiac dysrhythmias and changes in vital signs and hemodynamics</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I25.10</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atherosclerotic heart disease of native coronary artery without angina pectoris</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: First intervention group (aromatherapy with lavender essential oil): After assigning individuals to the intervention and placebo groups, the level of latent and overt anxiety will be measured using the Spielberger questionnaire. The second step: About an hour before angiography, for the lavender aromatherapy group, 2 drops of 10% lavender essential oil (provided by Barij Essential Oil Company) will be poured onto a 10 x 10 cm piece of cloth using a dropper and pinned to the patients' shirts 20 cm from their noses. Then, immediately 20 minutes after the intervention, the patients' level of anxiety will be measured again using the Spielberger questionnaire, and the data will be collected and analyzed. Finally, the results of the interventions between the groups, as well as before and after the intervention, will be analyzed and compared.</i_keyword>
      <i_keyword>Intervention group: Second intervention group (aromatherapy with chamomile essential oil): After assigning individuals to the intervention and placebo groups, the level of latent and overt anxiety will be measured using the Spielberger questionnaire. The second step is that about an hour before angiography, for the aromatherapy with chamomile essential oil group, 2 drops of 10% chamomile essential oil will be poured onto a 10 x 10 cm piece of cloth using a dropper and pinned to the patients' shirts at a distance of 20 cm from their noses. Then, immediately 20 minutes after the intervention, the patients' level of anxiety will be measured again using the Spielberger questionnaire, and data will be collected and analyzed. Finally, the results of the interventions between the groups, as well as before and after the intervention, will be analyzed and compared.</i_keyword>
      <i_keyword>Control group: (Aromatherapy with distilled water): After assigning individuals to the intervention and placebo groups, the level of latent and overt anxiety will be measured using the Spielberger questionnaire. The second step is that about an hour before angiography, for the placebo group, 2 drops of distilled water will be poured onto a 10 x 10 cm piece of cloth using a dropper and pinned to their shirt 20 cm from the patients' noses. Then, immediately 20 minutes after the intervention, the patients' level of anxiety will be measured again using the Spielberger questionnaire, and the data will be collected and analyzed. Finally, the results of the interventions between the groups, as well as before and after the intervention, will be analyzed and compared.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety level of angiography candidate patients. Timepoint: Measuring the anxiety level of angiography candidate patients before the intervention and twenty minutes after the intervention. Method of measurement: Spielberger's overt and covert anxiety test questionnaire, whose validity and reliability have been confirmed.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bandare-abbas University of Medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-01-08</approval_date>
        <contact_name>Ethics Committee of Hormozgan University of Medical Sciences</contact_name>
        <contact_address>Nursing and Midwifery Faculty, Hormozgan University of Medical Sciences , Beginning of Imam Hossein Boulevard Bandarabbas Hormozgan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
